engleski

Immunoglobulin G and total plasma protein N-glycosylation in Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative condition involving both motor and non-motor features. It is accompanied by dysfunction or loss of dopamine producing neurons in the substantia nigra pars compacta of the midbrain and the presence of Lewy bodies, cytoplasmic aggregations of the protein α-synuclein in brain neurons. Clinical symptoms of disease arise from this pathophysiology. Parkinson’s disease is occurring in about 1 % in individuals aged 60 years or older, in 4–5 % of those aged 85 years or older and it is estimated to afflict 0.3 % of the general population worldwide. The glycans covalently added on proteins, play important roles in almost every biological process, considering that all membrane and secreted proteins as well as numerous intracellular proteins are being modified by oligosaccharides. IgG N-glycosylation was analysed in 98 PD patients and in 95 patients as healthy controls and total plasma protein N-glycosylation was analysed in 107 PD patients and in 59 patients as healthy controls. Mono-galactosylated and digalactosylated IgG N-glycans are decreased in PD patients compared to the control group which follows the same trend as in some other inflammatory and autoimmune diseases as well as in aging (inflamaging). Galactosylation decreases proinflammatory function of IgG. This suggests the potential role of galactosylated IgG N-glycans as general biomarkers for aging, inflammatory and autoimmune diseases. Total protein plasma N-glycosylation should be investigated further in male population.

Parkinson's disease; IgG N-glycosylation

DOI: 10.1007/s10719-015-9596-4